Vasopressors/paralytics Flashcards Preview

Clinical Pharm > Vasopressors/paralytics > Flashcards

Flashcards in Vasopressors/paralytics Deck (104):
1

Phenylepherine MOA

Pure Alpha 1

2

Phenylepherine infusion dose range

20-200 mcg/min
0.15-1.0 mcg/kg/min

3

Phenylepherine bolus dose

40-100 mcg

4

Phenylepherine considerations

Increased SVR
Reflex bradycardia

5

Ephedrine MOA

Alpha 1, Beta 1
Indirect>direct
Causes NE release

6

Ephedrine bolus dose

5-25 mg

7

Ephedrine considerations

Increase HR
Tachyphylaxis

8

Epinephrine MOA

Alpha 1
Beta 1
Beta 2

9

Epinephrine infusion dose range

1-20 mcg/min
0.01-0.3 mcg/kg/min

10

Epinephrine bolus dose

10-500 mcg

11

Norepinephrine MOA

Alpha 1
Beta 1

12

Norepinephrine infusion dose

0.5-30 mcg/min
0.01-0.3 mcg/kg/min

13

Dopamine MOA

beta 1
Beta 2
Dopamine
Alpha 1

14

Dopamine infusion dose

1-20 mcg/kg/min

15

Vasopressin MOA

V1 SM
V2 CD

16

Vasopressin infusion dose

0.01-0.1 units/min
1-6 units/hr

17

Vasopressin bolus dose

1-10 units

18

Milrinone MOA

PDE III inhibitor

19

Milrinone infusion dose

0.375-0.75 mcg/kg/min

20

Milrinone bolus dose

50 mcg/kg over 10 minutes

21

Milrinone considerations

Increase CO and contractility

22

Phenylephrine concentration

100 mcg/mL
40 mcg/mL

23

Phenylephrine therapeutic effect

Increase SVR
Increase stroke volume
Increase venous return

24

Phenylephrine adverse effects

Reflex bradycardia

25

Phenylephrine clearance

Hepatic metabolism
Renal elimination

26

Ephedrine concentration

Dilute to 5 or 10 mg/ml

27

Ephedrine therapeutic effect

Increase HR
Increase venous return

28

Ephedrine adverse effects

Increase MVO2

29

Ephedrine clearance

Renal elimination

30

Epinephrine concentration

1:10,000 = 100 mcg/mL
1:1,000 = 1 mg/mL

31

Epinephrine therapeutic effect

Increase SVR
Increase HR
Increase contraction
Increase vascular resistance
Bronchodilaton

32

Epinephrine adverse effects

Increase glucose
Arrhythmogenic

33

Epinephrine clearance

MAO/COMT

34

Norepinephrine concentrations

4 mg/250 mL D5W

35

Norepinephrine adverse effects

Constrict microvascular
Oliguria

36

Norepinephrine clearance

MAO/COMT

37

Dopamine concentration

4 mg/250 mL D5W

38

Dopamine dose vs. MOA

5-10 B1>a1
10-20 a1>B1

39

Dopamine adverse effects

Tachyphylaxis
Oliguria

40

Dopamine MOA

MAO/COMT

41

vasopressin concentration

1 unit/mL
20 Units/mL in 20 mL NaCl

42

Vasopressin therapeutic effect

Increase SVR
Increase V1 smooth muscle

43

Vasopressin adverse effects

Pulmonary edema
GI ischemia

44

Vasopressin half life

10-20 min

45

Vasopressin clearance

Renal elimination

46

Milrinone concentration

50 mg/250 mL

47

Milrinone therapeutic effect

Increase contractility
Increase CO
Lusitropic
Decrease PVR

48

Milrinone adverse effects

Decrease BP
Ventricular arrythmias

49

Milrinone clearance

Hepatic metabolism
Renal elimination

50

Rocuronium class

Steroid

51

Rocuronium intubating dose

0.6-1.2 mg/kg

52

Rocuronium bolus dose

5-10 mg

53

Rocuronium RSI dose

1.2 mg/kg

54

Rocuronium concentration

10 mg/ml

55

Rocuronium onset

60-90 seconds

56

Rocuronium duration

30-60 minutes

57

Rocuronium considerations

Anaphylactoid
No hemodynamics changes

58

Rocuronium clearance

60% hepatic
30% renal

59

Rocuronium half life

1-2 hours

60

Vecuronium class

Steroid

61

Vecuronium intubating dose

0.1 mg/kg

62

Vecuronium bolus dose

1-4 mg

63

Vecuronium infusion dose

0.08-1.2 mcg/kg/min

64

Vecuronium concentration

1 mg/mL

65

Vecuronium onset

2-4 minutes

66

Vecuronium duration

30-60 minutes

67

Vecuronium considerations

Anaphylactoid
No hemodynamic changes

68

Vecuronium clearance

Hepatic 50%
Renal 50%

69

Pancuronium class

Steroid

70

Pancuronium intubating dose

0.1 mg/kg

71

Pancuronium bolus dose

1-2 mg

72

Pancuronium special considerations

Vagolytic

73

Pancuronium concentration

1 mg/ml

74

Pancuronium onset

2-4 min

75

Pancuronium duration

30-60 min

76

Pancuronium adverse effects

Increase HR, BP, CO

77

Pancuronium clearance

90% renal

78

Atracurium class

BISQ-AB

79

Atracurium intubating dose

0.5 mg/kg

80

Atracurium bolus dose

1-4 mg

81

Atracurium infusion dose

0.08-1.2 mcg/kg/min

82

Atracurium concentration

10 mg/ml

83

Atracurium onset

2-4 min

84

Atracurium duration

30-60 minutes

85

Atracurium clearance

Hofmann elimination
Plasma esterases

86

Cistracurium class

BISQ-AB

87

Cisatracurium intubating dose

0.15-0.2 mg/kg

88

Cisatracurium bolus dose

1-4 mg

89

Cisatracurium considerations

Renal/hepatic dysfunction

90

Cisatracurium concentration

2 mg/ml

91

Cisatracurium onset

2-4 min

92

Cisatracurium duration

30-60 minutes

93

Atracurium adverse effects

Increase HR
Decrease SVR
Histamine release

94

Cisatracurium clearance

Hofmann elimation
Plasma esterases

95

Cisatracurium adverse effects

None

96

Suxx class

Depolarizing

97

Suxx intubating dose

IV: 0.5-1.5 mg/kg
IM: 2-3 mg/kg

98

Suxx contraindications

MH
DMD
Burns
Rhbdo
Paralysis

99

Suxx dose used to treat laryngospasm

2-3 mg/kg

100

Suxx concentration

20 mg/ml

101

Suxx onset

30-60 seconds

102

Suxx duration

5-10 min

103

Suxx adverse effects

Bradycardia
Hyperkalemia
Myalgias
Increased ICP, IGP

104

Suxx clearance

Plasma pseudocholinesterase